Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Advances in Molecular PathologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- WHO classification of tumours of haematopoietic and lymphoid tissues.IARC Press, Lyon, France2017
- The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.Leukemia. 2022; 36: 1720-1748
- The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee.Blood. 2022; 140: 1229-1253
- Double-Hit Gene Expression Signature Defines a Distinct Subgroup of Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma.J Clin Oncol Off J Am Soc Clin Oncol. 2019; 37: 190-201
- MYC/BCL6 double-hit lymphoma (DHL): a tumour associated with an aggressive clinical course and poor prognosis.Histopathology. 2016; 68: 1090-1098
- Double-hit B-cell lymphomas with BCL6 and MYC translocations are aggressive, frequently extranodal lymphomas distinct from BCL2 double-hit B-cell lymphomas.Am. J. Surg. Pathol. 2013; 37: 323-332
- Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium.J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol. 2019; 37: 3359-3368
- Prognostic impact of concurrent MYC and BCL6 rearrangements and expression in de novo diffuse large B-cell lymphoma.Oncotarget. 2016; 7: 2401-2416
- Advances in pathological understanding of high-grade B cell lymphomas.Expert Rev Hematol. 2018; 11: 637-648
- Clinical, immunophenotypic, and genetic analysis of adult lymphomas with morphologic features of Burkitt lymphoma.Am J Surg Pathol. 2005; 29: 1086-1094
- Diagnosis of “double hit” diffuse large B-cell lymphoma and B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and Burkitt lymphoma: when and how, FISH versus IHC.Hematol Am Soc Hematol Educ Program. 2014; 2014: 90-99
- High-grade B-Cell Lymphoma With MYC, BCL2, and/or BCL6 Translocations/Rearrangements: Clinicopathologic Features of 51 Cases in a Single Institution of South China.Am. J. Surg. Pathol. 2020; 44: 1602-1611
- High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.Blood. 2018; 131: 2060-2064
- Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone.J Clin Oncol. 2012; 30: 3452-3459
- Double hit lymphoma: the MD Anderson Cancer Center clinical experience.Br J Haematol. 2014; 166: 891-901
- Mutational landscape of high-grade B-cell lymphoma with MYC-, BCL2 and/or BCL6 rearrangements characterized by whole-exome sequencing.Haematologica. 2021; 18https://doi.org/10.3324/haematol.2021.279631
- Triple-hit B-cell Lymphoma With MYC, BCL2, and BCL6 Translocations/Rearrangements: Clinicopathologic Features of 11 Cases.Am J Surg Pathol. 2015; 39: 1132-1139
- Outcomes of patients with double-hit lymphoma who achieve first complete remission.J Clin Oncol Off J Am Soc Clin Oncol. 2017; 35: 2260-2267
- Double-hit B-cell lymphomas.Blood. 2011; 117: 2319-2331
- Targeted next generation sequencing reveals high mutation frequency of CREBBP, BCL2 and KMT2D in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements.Haematologica. 2019; 104: e154-e157
- Double hit and double expressors in lymphoma: Definition and treatment.Cancer. 2018; 124: 4622-4632
- Current treatment of double hit and double expressor lymphoma.Hematol Am Soc Hematol Educ Program. 2017; 2017: 295-297
- IG-MYC + neoplasms with precursor B-cell phenotype are molecularly distinct from Burkitt lymphomas.Blood. 2018; 132: 2280-2285
- Diagnostic Approach for Double-Hit and Triple-Hit Lymphoma Based on Immunophenotypic and Cytogenetic Characteristics of Bone Marrow Specimens.Ann Lab Med. 2020; 40: 361-369
- High-grade B cell lymphoma, unclassifiable, with blastoid features: an unusual morphological subgroup associated frequently with BCL2 and/or MYC gene rearrangements and a poor prognosis.Histopathology. 2012; 61: 945-954
- High-resolution architecture and partner genes of MYC rearrangements in lymphoma with DLBCL morphology.Blood Adv. 2018; 2: 2755-2765
- MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study.Blood. 2015; 126: 2466-2474
- Inferior survival in high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements is not associated with MYC/IG gene rearrangements.Haematologica. 2018; 103: 1899-1907
- Integrating genomic alterations in diffuse large B-cell lymphoma identifies new relevant pathways and potential therapeutic targets.Leukemia. 2018; 32: 675-684
- Oncogenic MYD88 mutations are rare events in double-hit B-cell lymphomas.Acta Haematol. 2015; 133: 113-115
- TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations.Leuk Lymphoma. 2015; 56: 179-185
- The double-hit signature identifies double-hit diffuse large B-cell lymphoma with genetic events cryptic to FISH.Blood. 2019; 134: 1528-1532
- Distinct genetic changes reveal evolutionary history and heterogeneous molecular grade of DLBCL with MYC/BCL2 double-hit.Leukemia. 2020; 34: 1329-1341
- High-Grade B-Cell Lymphomas, Not Otherwise Specified: A Study of 41 Cases.Cancer Manag Res. 2020; 12: 1903-1912
- [Diagnosis and treatment in patients with B-cell lymphoma unclassified that is intermediate between diffuse large B-cell lymphoma and Burkitt’s lymphoma].Ter Arkh. 2015; 87: 77-85
- Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray.Blood. 2004; 103: 275-282
- The “Burkitt-like” immunophenotype and genotype is rarely encountered in diffuse large B cell lymphoma and high-grade B cell lymphoma, NOS.Virchows Arch Int J Pathol. 2021; 479: 575-583
- Mutational Landscape of TdT+ Large B-cell Lymphomas Supports Their Distinction From B-lymphoblastic Neoplasms: A Multiparameter Study of a Rare and Aggressive Entity.Am. J. Surg. Pathol. 2022; 46: 71-82
- Blastoid high-grade B-cell lymphoma initially presenting in bone marrow: a diagnostic challenge.Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc. 2022; 35: 419-426
- B-cell lymphoma, unclassifiable, with features intermediate between diffuse large B-cell lymphoma and burkitt lymphoma: study of 39 cases.Br J Haematol. 2013; 162: 40-49
- The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS.Am J Clin Pathol. 2018; 149: 17-28
- Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma.Haematologica. 2019; 104: 1822-1829
- A recurrent 11q aberration pattern characterizes a subset of MYC-negative high-grade B-cell lymphomas resembling Burkitt lymphoma.Blood. 2014; 123: 1187-1198
- Post-transplant molecularly defined Burkitt lymphomas are frequently MYC-negative and characterized by the 11q-gain/loss pattern.Haematologica. 2015; 100: e275-e279
- Aggressive B-cell lymphoma cases with 11q aberration patterns indicate a spectrum beyond Burkitt-like lymphoma.Blood Adv. 2021; 5: 5220-5225
- A Diagnostic Approach to the Identification of Burkitt-like Lymphoma With 11q Aberration in Aggressive B-Cell Lymphomas.Am. J. Surg. Pathol. 2021; 45: 356-364
- Experience with provisional WHO-entities large B-cell lymphoma with IRF4-rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group.Br. J. Haematol. 2020; 190: 753-763
- The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS.Am J Clin Pathol. 2017; 149: 17-28
- Partial trisomy 11, dup(11)(q23q13), as a defect characterizing lymphomas with Burkitt pathomorphology without MYC gene rearrangement.Med Oncol Northwood Lond Engl. 2011; 28: 1589-1595
- The peculiar 11qgain/ loss aberration reported in a subset of MYCnegative high-grade B-cell lymphomas can also occur in a MYC-rearranged lymphoma.Cancer Genet. 2016; 209: 117-118
- A comprehensive flow-cytometry-based immunophenotypic characterization of Burkitt-like lymphoma with 11q aberration.Mod Pathol. 2018; 31: 732-743
- Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma.Blood. 2014; 123: 1681-1690
- miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2015; 36: 5377-5388
- The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.Blood. 2019; 133: 962-966
- False-negative rates for MYC fluorescence in situ hybridization probes in B-cell neoplasms.Haematologica. 2019; 104: e248-e251
- Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations.Leukemia. 2021; 35: 3059-3072
- The Minimal Residual Disease in Non-Hodgkin’s Lymphomas: From the Laboratory to the Clinical Practice.Front Oncol. 2019; 9: 528
- Are We Ready to Treat Diffuse Large B-cell and High-Grade Lymphoma According to Major Genetic Subtypes?.HemaSphere. 2019; 3: e284
Article info
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
